Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934127 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 427
- Enrollment target
NCT01934127 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 427 participants.
The verdict
NCT01934127, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 427 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine and placebo.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Investigational H7N1 vaccine GSK2789869A
- BIOLOGICAL Investigational H7N1 vaccine GSK2789868A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2013-08-26 |
| Est. Completion | 2014-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01934127
The ClinicalTrials.gov registry entry for NCT01934127 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01934127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01934127 about?
NCT01934127 is a clinical study titled "Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age". The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine and pla...
What is the current status of trial NCT01934127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 427 participants. The study started on 2013-08-26. Estimated completion is 2014-10-20.
What interventions are being tested in trial NCT01934127?
The interventions under investigation include: Placebo (BIOLOGICAL), Investigational H7N1 vaccine GSK2789869A (BIOLOGICAL), Investigational H7N1 vaccine GSK2789868A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01934127?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.